Drug Discovery World

JUNE 29, 2023

To mark the occasion, this article summarises the most recent news about the ways drug discovery is improving wellbeing and mental health through innovative new treatments and therapies.

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

BioTech 365

FEBRUARY 10, 2021

DGAP-News: XPhyto Therapeutics Corp. / XPhyto Adds Mescaline Production to Psychedelic Medicine Programs VANCOUVER, BC / ACCESSWIRE / February 10, 2021 / XPhyto … Continue reading → Key word(s): Miscellaneous 10.02.2021 / 09:05 The issuer is solely responsible for the content of this announcement.

Medicine 40

Medicine Production 40

BioTech 365

FEBRUARY 3, 2021

DGAP-News: XPhyto Therapeutics Corp. / XPhyto Announces Psychedelic Pharmaceutical Production Agreement VANCOUVER, BC / ACCESSWIRE / February 3, 2021 / XPhyto Therapeutics Corp. Key word(s): Miscellaneous 03.02.2021 / 09:05 The issuer is solely responsible for the content of this announcement. … Continue reading →

Production 40

Production 40

BioTech 365

OCTOBER 16, 2020

NEW YORK, Oct. announces the availability of a broadcast titled, “Multi-Billion-Dollar Market Forecast in Psychedelic Therapeutics.” ” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, … Continue reading →

Marketing 40

Marketing 40

Drug Discovery World

NOVEMBER 4, 2022

News round-up for 31 October – 4 November by DDW Digital Content Editor Diana Spencer . In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Study shows ‘magic mushrooms’ could treat depression .

Gene Therapy 52

Gene Therapy Drugs Antibody Gene 52

The Pharma Data

DECEMBER 20, 2020

It is our continual objective to broaden our product scope, and Transcend, with its experienced management team, is a perfect foothold for us in the fast-growing market for psychedelics molecules and complements our existing pipeline of treatments. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS. Source link.

Drug Delivery 52

Drug Delivery Containment Production Development 52

The Pharma Data

JANUARY 18, 2021

In yesterday’s online edition of Forbes magazine, Ahmad Doroudian, CEO of BetterLife, further emphasized the significant barriers that current regulations impose on development of the current generation of psychedelics and LSD based compounds and advantages of non-controlled second generation psychedelics such as TD-0148A.

Containment 40

Containment Regulation Production Drug Delivery 40

The Pharma Data

DECEMBER 14, 2020

While the medicalization of psychedelics is evolving and gaining momentum at an extraordinary pace, such therapeutics still face regulatory hurdles in the areas of manufacturing, formulating, and ultimately dispensing or the rescheduling of Schedule I drugs to patients. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS.

Drug Delivery 40

Drug Delivery Containment Manufacturing Drugs 40

The Pharma Data

NOVEMBER 9, 2020

Psilocybin, mescaline, LSD, MDMA, DMT and other psychedelic compounds added to exclusive dealing agreement for the development of psychedelic-based therapeutics. Dr. Löbenberg have recently signed an addendum to the Exclusive Dealing Agreement to include psychedelic compounds. DMT (N,N-dimethyltryptamine).

Development 40

Development Drugs Drug Delivery Production 40

The Pharma Data

JANUARY 17, 2021

Psychedelic API production, drug formulation and clinical integration. Psychedelics. Psychedelics could provide a major improvement over currently available therapeutics for a global market with unmet medical need. Commercialization of rapid COVID-19 PCR test. Diagnostics.

Production 40

Production Drug Delivery Development Drugs 40

The Pharma Data

NOVEMBER 2, 2020

The Company has identified a number of psychedelic compounds that are emerging as strong potential candidates for the treatment of mental health related medical indications such as depression, anxiety, addiction, anorexia and post-traumatic stress disorder. “Psychedelic agents are a promising new class of therapeutic drug.

Production 52

Production Development Drug Delivery Drugs 52

Worldwide Clinical Trials

OCTOBER 19, 2022

BioPharma Dive interviewed our Christine Moore on how to conduct psychedelic clinical research. Psychedelic products are having a renaissance moment. As evidence emerges about their potential for PTSD, depression, cancer-related distress and more, the market for psychedelics could swell from $2 billion in 2020 to $10.75

Clinical Trials 130

Clinical Trials Clinical Trials Trials Production 130

The Pharma Data

DECEMBER 28, 2020

28, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“ BetterLife ” or the “ Company ”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. VANCOUVER, Dec. Source link.

Containment 52

Containment Drug Delivery Compliance Marketing 52

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Other news saw Innovate UK invest almost £500,000 in biopharmaceutical company Orbit Discovery to help expand its microfluidics screening capabilities.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

DECEMBER 26, 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Compound that can block cancer metastasis In DDW’s most-read news stoy of 2023, researchers from the University of Liverpool, UK, created a biomedical compound that has the potential to stop the spread of breast cancer.

Development 64

Development Clinical Trials Clinical Trials Drugs 64

Drug Discovery World

OCTOBER 25, 2022

Under the terms of the agreement, which has been approved by shareholders, Beckley Psytech has acquired 100% of Eleusis, receiving full developmental and commercial rights for the company’s assets which will further enhance Beckley Psytech’s innovative and differentiated pipeline of psychedelic compounds. . Official comments .

Life Science 52

Life Science Clinical Trials Clinical Trials Development 52

The Pharma Data

JANUARY 27, 2021

Psychedelic transdermal and sublingual drug formulation development. We will be building on significant momentum from 2020 as we advance our drug formulation, contract development, and psychedelic business,” said Prof. Construction of commercial drug manufacturing facility in Germany.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Drug Discovery World

APRIL 2, 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.

FDA Approval 59

FDA Approval Antibody Trials Drugs 59

pharmaphorum

AUGUST 16, 2021

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. Beckley – formerly known as Beckley Canopy Therapeutics – raised £7.4

Development 135

Development Medicine Clinical Development Research 135

Drug Discovery World

DECEMBER 27, 2023

There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. You can listen below, or find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

FDA Approval 52

FDA Approval Antibody Drugs Trials 52

Drug Discovery World

JULY 11, 2022

Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US. . Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD).

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

Drug Discovery World

NOVEMBER 6, 2023

The news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist. The latest episode of the DDW Highlights podcast is now available to listen to below.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Trials 52

pharmaphorum

MAY 19, 2022

Phase 2 trials of Beckley Psytech’s psychedelic drug candidates will make use of digital technologies for patient monitoring, thanks to a new partnership with Empatica. Eventually, it intends to layer in digital monitoring as a fundamental component in the development of all its psychedelic-assisted psychotherapy programmes.

Drug Trials 94

Drug Trials Trials Drugs Development 94

pharmaphorum

SEPTEMBER 14, 2021

The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare disorder. The UK company says that SUNHA is a debilitating condition that is estimated to affect 40,000 patients in US and Europe.

Trials 98

Trials Medicine Clinical Trials Clinical Trials 98

XTalks

JANUARY 6, 2021

Psychedelic drugs are rapidly becoming mainstream as various research supports their effectiveness in alleviating mental health problems. Psychedelic drugs such as LSD, psilocybin, ketamine and more are being studied to explore their effects on mental illnesses, like depression. Mind Medicine.

Drugs 97

Drugs Clinical Trials Clinical Trials Medicine 97

Drug Discovery World

JULY 25, 2023

Interim findings from the Phase I/IIa study have also demonstrated positive observations, showing that CYB003 dosing led to a rapid and robust psychedelic response in participants at low doses, while maintaining a safe and well-tolerated therapeutic profile.

Trials 52

Trials Bioequivalency Clinical Trials Clinical Trials 52

Drug Discovery World

JUNE 27, 2023

The US Food and Drug Administration (FDA) has published new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for the potential treatment of medical conditions, including psychiatric or substance use disorders. However, these are still investigational products.

Development 52

Development Drugs Clinical Trials Clinical Trials 52

pharmaphorum

APRIL 16, 2021

Researchers at Imperial College London’s Centre for Psychedelic Research also say that psilocybin may have a stronger effect and was more likely to help patients achieve remission from depression, although they stress the study was small and more research is needed.

Clinical Trials 101

Clinical Trials Clinical Trials Trials Research 101

pharmaphorum

MAY 5, 2021

The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) is leading the development of MDMA and has just reported top-line results from a phase 3 trial of the drug combined with psychotherapy that it says could form the basis of a marketing application to the US regulator.

Development 96

Development FDA Approval Trials Medicine 96

pharmaphorum

OCTOBER 2, 2020

Psychedelic therapy company Field Trip Psychedelics has announced that it will soon join the growing list of psychedelic companies going public. . The post Field Trip becomes latest psychedelic firm to go public appeared first on. Phase 1 first-in-man pharmacokinetic studies are expected to start in Q4 2021.

Medicine 107

Medicine Life Science FDA Approval Development 107

Drug Discovery World

APRIL 10, 2023

BPL-003 is Beckley Psytech’s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. The post Phase IIa study will investigate psychedelic for alcohol use disorder appeared first on Drug Discovery World (DDW).

FDA Approval 52

FDA Approval Development Research Drugs 52

pharmaphorum

MAY 7, 2021

Small Pharma is following the trend for development of psychedelic medicines, a field where research has been suppressed for years because of legal restrictions on use of these compounds in many countries.

Drug Trials 83

Drug Trials Trials Marketing Drugs 83

Drug Discovery World

NOVEMBER 15, 2022

The drug is under development for Treatment Resistant Depression and Alcohol Use Disorder and was assessed in combination with psychological support in 44 psychedelic-naïve participants. . The post Synthetic psychedelic successfully completes Phase I study appeared first on Drug Discovery World (DDW).

Development 52

Development Drugs Trials 52

Drug Discovery World

NOVEMBER 7, 2022

In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. The latest episode of the DDW Highlights podcast is now available to listen to below.

Vaccination 52

Vaccination Vaccine Drugs 52

pharmaphorum

JANUARY 6, 2022

Despite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary of getting involved, leaving the task to small start-ups. MSRD has agreed to provide financial and operational support to the development of two families of Mindset’s psychedelic compounds through phase 1a /1b testing.

Development 62

Development Clinical Trials Clinical Trials Sales 62

Scienmag

MARCH 22, 2022

Because existing treatments don’t work for everyone, new therapies are urgently needed. SAN DIEGO, March 22, 2022 — Post-traumatic stress disorder (PTSD) affects millions of people each year, mostly survivors and witnesses of terrifying or shocking events, such as warfare, assaults or disasters.

Scientist 64

Scientist Drugs 64

Drug Discovery World

JULY 15, 2022

News round-up by DDW’s Reece Armstrong for 11 – 15 July. Urgency a must for global fight against AMR, report says. Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO).

Life Science 52

Life Science Drugs Vaccination Vaccine 52